Coverage · Source update
Which Zepbound and Wegovy forms qualify for the Bridge?
Source context: Read the linked original research or registry entry for study status and limitations.
CMS published pharmacy guidance for its Medicare GLP-1 Bridge that distinguishes between different forms of weight-loss medicines. This is especially important for people who know the brand name but not the precise device or formulation. We explain what the federal program lists and why a Zepbound vial and a Zepbound KwikPen may receive different treatment.
Eligible product formulations
CMS published pharmacy guidance for its Medicare GLP-1 Bridge that distinguishes between different forms of weight-loss medicines. This is especially important for people who know the brand name but not the precise device or formulation. We explain what the federal program lists and why a Zepbound vial and a Zepbound KwikPen may receive different treatment.
What does the original source show?
The FAQ lists all Foundayo and Wegovy formulations and Zepbound KwikPen. It excludes Zepbound single-dose vials and single-dose pens. Device format therefore matters, even within one brand.
Why does it matter?
A brand can come in different delivery devices, such as tablets, multidose pens or single-use presentations. Manufacturers may offer several versions, but a coverage program can specify exactly which ones it accepts. That is why 'Zepbound covered' can be an incomplete statement.
What should readers keep in mind?
When checking a prescription, compare the full product name and delivery form with the current CMS list. If the form differs, ask your pharmacist or prescriber about approved options; do not independently change medication or dosing. Product lists and program terms may be updated.
The practical takeaway
Confirm the exact prescribed presentation against CMS's current eligible-product list.
The bottom line
Confirm the exact prescribed presentation against CMS's current eligible-product list.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-08-06. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceAdditional evidenceSource event or update: 2026-08-06. Our interpretation is educational and does not replace medical or insurance advice.